Multiple Tumor Types

Viewing Page 2 of 7 | Showing Results 11 - 20 of 61

Caris Molecular Intelligence® and Caris Centers of Excellence for Precision Medicine NetworkTM Outcomes Associated Repository

a research repository (a database of information), which will be used for research studies to evaluate how clinical outcomes relate to Caris...

Michael Demeure, M.D.
  • Hoag Research
  • xSJH Southern California

A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients.

This trial studies treatment effects on development of chemotherapy-induced peripheral neuropathy in patients with cancer. Treatments for cancer...

Gary Goodman, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Montana, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

Molecular Analysis for Therapy Choice (MATCH)

This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Montana, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and...

Walter Urba, M.D., Ph.D.
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Clackamas Clinic
  • Providence Cancer Institute Franz Clinic
  • Providence Cancer Institute Newberg Clinic

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms

The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD013 and establish the maximum tolerated dose (MTD) of...

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-106 in Subjects with Locally Advanced or Metastatic Solid Tumors (2020000213)

This is a first-in-human, open-label, non-randomized, 4-part Phase 1 trial to determine the safety profile and identify the maximum tolerated dose...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers

This study evaluates the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study is being conducted in...

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)

The purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered prior to Definitive Surgical Resection in Patients with Head and Neck Squamous Cell Carcinoma or Melanoma (AZ ESR-16-12559)

This clinical trial is the first to evaluate the safety and feasibility of a humanized OX40 agonist, MEDI0562, in the pre-operative setting for...

Brendan Curti, M.D.
  • Providence Cancer Institute Franz Clinic

EAY 131: Molecular Analysis for Therapy Choice (MATCH)

Isaac Tafur, M.D.
  • Covenant Health
Viewing Page 2 of 7 | Showing Results 11 - 20 of 61